CTLA4 and acute myeloid leukemia: Response rates were promising (i.e., 59% for anti-CTLA-4, and 33% for anti-PD-1 in the high dosage trials), but due to the potential for immune related toxicity in AML patients, the use of checkpoint blockade has not moved forward for this leukemia [13,18,19].